| Related Articles |
The prognostic role of gender and MGMT methylation status in glioblastoma patients: the female power.
World Neurosurg. 2018 Jan 11;:
Authors: Franceschi E, Tosoni A, Minichillo S, Depenni R, Paccapelo A, Bartolini S, Michiara M, Pavesi G, Urbini B, Crisi G, Cavallo MA, Tosatto L, Dazzi C, Biasini C, Pasini G, Balestrini D, Zanelli F, Ramponi V, Fioravanti A, Giombelli E, De Biase D, Baruzzi A, Brandes AA, PERNO Study Group
Abstract
BACKGROUND: Clinical and molecular factors are essential to define prognosis in glioblastoma (GBM) patients. MGMT methylation status, age, Karnofsky performance status (KPS) and extent of surgical resection are the most relevant prognostic factors. The role of gender in predicting patients prognosis has been investigated showing a slight survival advantage for female patients.
METHODS: We performed a prospective evaluation from a registry called the Project of Emilia Romagna on Neuro-Oncology (PERNO) about prognostic factors in GBM patients who received standard treatment.
RESULTS: One hundred sixty-nine patients were prospectively evaluated. Among male patients 36 were MGMT methylated (25.7%) and 47 were unmethylated (33.6%); among female patients 32 were methylated (22.9%) and 25 were unmethylated (17.9%). Survival was longer in methylated females than methylated males (p=0.028) but not significantly different between unmethylated female and male patients (P=0.395). In multivariate analysis, gender and MGMT methylation status considered together (methylated female vs methylated male HR=0.459; 95% CI 0.242 - 0.827; P=0.017), age (HR 1.025; 95% CI 1.002 - 1.049; P= 0.032) and KPS (HR 0.965; 95% CI 0.948 - 0.982; P< 0.001) were significantly correlated with survival.
CONCLUSION: Survival was consistently longer among MGMT methylated females than males. Gender could be regarded as a further prognostic factor.
PMID: 29337169 [PubMed - as supplied by publisher]
http://ift.tt/2EUKizg
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου